Deutsche Bank AG Grows Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

Deutsche Bank AG raised its position in Acelyrin, Inc. (NASDAQ:SLRN) by 53.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 70,000 shares of the company’s stock after purchasing an additional 24,356 shares during the period. Deutsche Bank AG’s holdings in Acelyrin were worth $220,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in shares of Acelyrin by 21.9% during the fourth quarter. Wells Fargo & Company MN now owns 52,014 shares of the company’s stock worth $163,000 after purchasing an additional 9,332 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Acelyrin during the fourth quarter worth about $33,000. Boothbay Fund Management LLC increased its stake in shares of Acelyrin by 54.8% during the fourth quarter. Boothbay Fund Management LLC now owns 29,828 shares of the company’s stock worth $94,000 after purchasing an additional 10,554 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock worth $83,000 after purchasing an additional 11,040 shares in the last quarter. Finally, 4WEALTH Advisors Inc. purchased a new stake in shares of Acelyrin during the fourth quarter worth about $35,000. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Insider Activity at Acelyrin

In related news, CEO Mina Kim sold 17,986 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. This represents a 2.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.60% of the stock is owned by corporate insiders.

Acelyrin Price Performance

SLRN stock opened at $2.27 on Tuesday. The stock has a market capitalization of $229.17 million, a P/E ratio of -0.92 and a beta of 1.07. The firm has a 50-day simple moving average of $2.32 and a 200-day simple moving average of $2.69. Acelyrin, Inc. has a 52 week low of $1.85 and a 52 week high of $7.25.

Acelyrin (NASDAQ:SLRN) last released its earnings results on Wednesday, May 14th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.40. On average, analysts expect that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.